Difference between revisions of "Team:SYSU-MEDICINE/Proof"

(Replaced content with "{{SYSU-MEDICINE}} <html> </html>")
 
(8 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{SYSU-MEDICINE}}
 
 
 
<html>
 
<html>
  
  
  
 +
 +
<head>
 +
    <meta charset="UTF-8">
 +
    <link rel="icon" type="image/png" href="https://static.igem.org/mediawiki/2016/2/2a/T--SYSU-MEDICINE--logo_32%2A32.png" sizes="16x16">
 +
    <link rel="icon" type="image/png" href="https://static.igem.org/mediawiki/2016/2/2a/T--SYSU-MEDICINE--logo_32%2A32.png" sizes="32x32">
 +
    <!-- Latest compiled and minified CSS -->
 +
    <!--<link href='//cdn.webfont.youziku.com/webfonts/nomal/92549/46882/57f3d7e1f629d81a5077d03f.css' rel='stylesheet' type='text/css' />-->
 +
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/css/bootstrap.min.css" integrity="sha384-BVYiiSIFeK1dGmJRAkycuHAHRg32OmUcww7on3RYdg4Va+PmSTsz/K68vbdEjh4u" crossorigin="anonymous">
 +
    <!--jQuery-->
 +
    <script  src="https://code.jquery.com/jquery-3.1.1.min.js"  integrity="sha256-hVVnYaiADRTO2PzUGmuLJr8BLUSjGIZsDYGmIJLv2b8="  crossorigin="anonymous"></script>
 +
    <!-- Latest compiled and minified JavaScript -->
 +
    <script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/js/bootstrap.min.js" integrity="sha384-Tc5IQib027qvyjSMfHjOMaLkfuWVxZxUPnCJA7l2mCWNIpG9mGCD8wGNIcPD7Txa" crossorigin="anonymous"></script>
 +
    <style>
 +
        /*font*/
 +
        /*font*/
 +
        @font-face{font-family:"HelveticaNeueW02-45Ligh";src:url('//www.eyeem.com/css/fonts/88fcd49a-13c7-4d0c-86b1-ad1e258bd75d.eot?#iefix');src:url('//www.eyeem.com/css/fonts/88fcd49a-13c7-4d0c-86b1-ad1e258bd75d.eot?#iefix') format("eot"),url('//www.eyeem.com/css/fonts/9a2e4855-380f-477f-950e-d98e8db54eac.woff') format("woff"),url('//www.eyeem.com/css/fonts/fa82d0ee-4fbd-4cc9-bf9f-226ad1fcbae2.ttf') format("truetype"),url('//www.eyeem.com/css/fonts/48d599a6-92b5-4d43-a4ac-8959f6971853.svg#48d599a6-92b5-4d43-a4ac-8959f6971853') format("svg")}
 +
        *{
 +
            font-family:"HelveticaNeueW02-45Ligh","Arial",sans-serif;
 +
            letter-spacing: 0.4px;
 +
            line-height: 1.5em;
 +
        }
 +
        #HQ_page h1,#HQ_page h2,#HQ_page h3,#HQ_page h4,#HQ_page h5,#HQ_page p{
 +
            font-family:"HelveticaNeueW02-45Ligh","Arial",sans-serif;
 +
        }
 +
        #HQ_page p{
 +
            font-size: 20px;
 +
        }
 +
        #HQ_page td{
 +
            padding:0;
 +
            border:0;
 +
        }
 +
        #HQ_page table {
 +
            border:0;
 +
        }
 +
        /*override wiki*/
 +
        .menu_wrapper, #top_title, #sideMenu{display: none;}
 +
        #content {
 +
            width:100%;
 +
            padding:0;
 +
            margin: 16px auto;
 +
        }
 +
        #top_menu_under {
 +
            height: 0;
 +
        }
 +
        #top_menu_14 {
 +
            border-bottom: 0;
 +
        }
 +
        #globalWrapper {
 +
            font-size: 100%;
 +
            padding-bottom: 0;
 +
        }
 +
        #content {
 +
            margin-bottom: 0;
 +
        }
 +
        /*nav*/
 +
        .navbar {
 +
            border-radius: 0;
 +
            height: 50px;
 +
            margin-bottom:0;
 +
            z-index: 25;
 +
        }
 +
        .navbar-inverse .navbar-brand {
 +
            color: #fff;
 +
        }
 +
        .navbar-inverse .navbar-nav>.active>a, .navbar-inverse .navbar-nav>.active>a:focus, .navbar-inverse .navbar-nav>.active>a:hover {
 +
            background-color: rgba(0,0,0,0);
 +
            color: #999;
 +
            font-weight:600;
 +
        }
 +
        .navbar-inverse .navbar-nav>li>a {
 +
            color: #fff;
 +
            font-weight:600;
 +
        }
 +
        .navbar-inverse .navbar-nav>li>a:hover {
 +
            color: #999;
 +
            font-weight:600;
 +
        }
 +
        .navbar-nav>li{
 +
            top: -5px;
 +
        }
 +
        /*.mw-content-ltr ul, .mw-content-rtl .mw-content-ltr ul {*/
 +
        /*margin: 0 0.1;*/
 +
        /*}*/
 +
        .dropdown-menu>li>a {
 +
            font-weight: 600;
 +
        }
 +
        .third-level-list {
 +
            top: -10px;
 +
            left: 150px;
 +
        }
 +
        .jumbotron{
 +
            margin-bottom:0;
 +
            padding-top:10px;
 +
            padding-bottom:20px;
 +
        }
 +
        #jumbo-footer.jumbotron {
 +
            padding-top: 10px;
 +
            padding-bottom: 30px;
 +
            margin-bottom: 0;
 +
        }
 +
        #jumbo-footer.jumbotron>.footer-container{
 +
            width: 1170px;
 +
            margin: 20px auto;
 +
            font-size: 18px;
 +
            color: #888;
 +
            /*font-weight: bold;*/
 +
        }
 +
        #jumbo-footer.jumbotron>.footer-container .line{
 +
            height: 2px;
 +
            background-color: #bbb;
 +
            width: 100%;
 +
        }
 +
        #jumbo-footer.jumbotron>.footer-container .contact {
 +
            margin-top: 20px;
 +
            margin-left: 10px;
 +
            height: 140px;
 +
        }
 +
        #jumbo-footer.jumbotron>.footer-container .title{
 +
            font-weight: bold;
 +
        }
 +
        #jumbo-footer.jumbotron>.footer-container .contact ul{
 +
            list-style: none;
 +
            padding-left: 0;
 +
            margin-left: 0;
 +
        }
 +
        #jumbo-footer.jumbotron>.footer-container .contact ul.float-contact {
 +
            float:left;
 +
            width: 400px;
 +
        }
 +
        #jumbo-footer.jumbotron>.footer-container .contact ul li {
 +
            margin-top: 5px;
 +
            margin-bottom: 5px;
 +
        }
 +
        #jumbo-footer.jumbotron>.footer-container .contact ul li a img{
 +
            width: 30px;
 +
            height: 30px;
 +
        }
 +
        #jumbo-footer.jumbotron>.footer-container .contact ul li a {
 +
            color: #888;
 +
        }
 +
        #jumbo-footer.jumbotron>.footer-container .contact ul li a:hover, #jumbo-footer.jumbotron>.footer-container .contact ul li a:active, #jumbo-footer.jumbotron>.footer-container .contact ul li a:focus {
 +
            color: #888;
 +
            text-decoration: none;
 +
        }
 +
        #jumbo-footer.jumbotron>.footer-container .contact .float-contact-right {
 +
            float:right;
 +
        }
 +
        #jumbo-footer.jumbotron>.footer-container .copyright{
 +
            margin-top: 5px;
 +
        }
 +
        #jumbo-footer.jumbotron>.footer-container .copyright .text {
 +
            font-size: 16px;
 +
            float: left;
 +
        }
 +
        #jumbo-footer.jumbotron>.footer-container .copyright .icon{
 +
            float: right;
 +
        }
 +
        #jumbo-footer.jumbotron>.footer-container .copyright .icon img {
 +
            width: 25px;
 +
            height: 25px;
 +
        }
 +
        #wechatModal .modal-dialog{
 +
            width: 332px;
 +
            margin-top: 100px;
 +
            z-index: 2000;
 +
        }
 +
        /*content*/
 +
        .jumbotron .my-content{
 +
            margin: 0 auto;
 +
            width: 900px;
 +
        }
 +
        .jumbotron .my-content h2 {
 +
            text-align: center;
 +
            font-weight: bolder;
 +
            font-size: 40px;
 +
            margin-bottom:30px;
 +
        }
 +
        .jumbotron .my-content p {
 +
            line-height: 1.5em;
 +
            font-size: 20px;
 +
            color: #333;
 +
        }
 +
        .jumbotron#content{
 +
            background-color: #fff;
 +
        }
 +
        .jumbotron#content p a{
 +
            color: #333;
 +
        }
 +
        .jumbotron#content img{
 +
            width: 90%;
 +
            margin: 10px auto;
 +
            display: block;
 +
        }
 +
        .jumbotron#content span.note{
 +
            width: 80%;
 +
            font-size: 16px;
 +
            color: #999;
 +
            margin: 0 auto;
 +
            display: block;
 +
        }
 +
        /*mynav*/
 +
        .mynav{
 +
            position: fixed;
 +
            /*width:250px;*/
 +
            left: 10px;
 +
            opacity: 0.2;
 +
            top: 300px;
 +
            background-color: #f2f2f2;
 +
            border-radius: 10px;
 +
            -webkit-transition: opacity 0.2s, width 0.2s;
 +
            -moz-transition: opacity 0.2s, width 0.2s;
 +
            -ms-transition: opacity 0.2s, width 0.2s;
 +
            -o-transition: opacity 0.2s, width 0.2s;
 +
            transition: opacity 0.2s, width 0.2s;
 +
            padding-right: 20px;
 +
        }
 +
        .mynav:hover {
 +
            opacity: 1;
 +
 +
        }
 +
        .mynav ol{
 +
            list-style: none;
 +
            padding-left:20px;
 +
            margin:0;
 +
 +
        }
 +
        .mynav ol li ol{
 +
            display:none;
 +
        }
 +
        .mynav li a{
 +
            color: #333;
 +
            font-size: 18px;
 +
            width: 300px;
 +
        }
 +
        .mynav li a:hover, .mynav li a:active,.mynav li a:focus{
 +
            color:#e57d22;
 +
        }
 +
        .mynav li li a{
 +
            font-size: 16px;
 +
        }
 +
        .mynav li li li a{
 +
            font-size: 14px;
 +
        }
 +
    </style>
 +
    <script type="text/javascript">
 +
        $(document).ready(function() {
 +
//          wechat qr code
 +
            var canHide= true;
 +
            $('#wechatModal').on('show.bs.modal', function (e) {
 +
                // do something...
 +
                $("#wechatModal").after('<div class="modal-backdrop fade in"></div>');
 +
            });
 +
            $(".modal").click(function() {
 +
//                console.log("click");
 +
                //$(this).remove();
 +
                if (canHide) {
 +
                    $(".modal-backdrop").remove();
 +
                    $('#wechatModal').modal('hide');
 +
                }
 +
            });
 +
            $(".modal-dialog").click(function() {
 +
                canHide = false;
 +
            });
 +
            $(".modal").mousemove(function() {
 +
                canHide = true;
 +
            });
 +
            $(".third-level-list").css("left", "120px");
 +
//          third level menu on nav
 +
            $(".third-level-menu").mouseenter(function() {
 +
                console.log("mouse in");
 +
                $(this).addClass("open");
 +
 +
            });
 +
            $(".third-level-menu").mouseleave(function() {
 +
                console.log("mouse in");
 +
                $(this).removeClass("open");
 +
            });
 +
            $(".dropdown").mouseenter(function() {
 +
                $(this).addClass("open");
 +
            });
 +
            $(".dropdown").mouseleave(function() {
 +
                $(this).removeClass("open");
 +
            });
 +
            //            mynav
 +
            $(".mynav li").mouseenter(function() {
 +
                $(this).children('ol').slideDown();
 +
            });
 +
            $(".mynav li").mouseleave(function() {
 +
                $(this).children('ol').slideUp();
 +
            })
 +
        });
 +
    </script>
 +
</head>
 +
<body>
 +
<nav class="navbar navbar-inverse">
 +
    <div class="container-fluid">
 +
        <!-- Brand and toggle get grouped for better mobile display -->
 +
        <div class="navbar-header">
 +
            <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#bs-example-navbar-collapse-1" aria-expanded="false">
 +
                <span class="sr-only">Toggle navigation</span>
 +
                <span class="icon-bar"></span>
 +
                <span class="icon-bar"></span>
 +
                <span class="icon-bar"></span>
 +
            </button>
 +
            <a class="navbar-brand" href="https://2016.igem.org/Team:SYSU-MEDICINE">
 +
                <img style="height: 40px; width: 40px; margin-top: -10px " src="https://2016.igem.org/wiki/skins/Igem/images/IGEM_white_letters.png">
 +
            </a>
 +
            <a class="navbar-brand" href="https://2016.igem.org/Team:SYSU-MEDICINE">SYSU-MEDICINE</a>
 +
        </div>
 +
 +
        <!-- Collect the nav links, forms, and other content for toggling -->
 +
        <div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1">
 +
            <ul class="nav navbar-nav navbar-right">
 +
                <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE">HOME</a></li>
 +
                <li class="dropdown active">
 +
                    <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">PROJECT<span class="caret"></span></a>
 +
                    <ul class="dropdown-menu">
 +
                        <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Description">Description</a></li>
 +
                        <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Results">Results</a></li>
 +
                        <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Protocol">Protocol</a></li>
 +
                        <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Notebook">Notebook</a></li>
 +
                        <li class="dropdown third-level-menu">
 +
                            <a href="#" class="dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">For Judgement <span class="glyphicon glyphicon-chevron-right"></span></a>
 +
                            <ul class="third-level-list dropdown-menu">
 +
                                <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Proof">Proof of Concept</a></li>
 +
                                <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Demonstrate">Demonstrate</a></li>
 +
                            </ul>
 +
                        </li>
 +
                    </ul>
 +
                </li>
 +
                <li class="dropdown">
 +
                    <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">HUMAN PRACTICES<span class="caret"></span></a>
 +
                    <ul class="dropdown-menu">
 +
                        <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Our_Story">Our Story</a></li>
 +
                        <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Interview">Interview</a></li>
 +
                        <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Ethics">Ethics</a></li>
 +
                        <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Legislation">Legislation</a></li>
 +
                        <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Products">Products</a></li>
 +
                        <li class="dropdown third-level-menu">
 +
                            <a href="#" class="dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">For Judgement <span class="glyphicon glyphicon-chevron-right"></span></a>
 +
                            <ul class="third-level-list dropdown-menu">
 +
                                <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/HP/Silver">Silver</a></li>
 +
                                <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/HP/Gold">Gold</a></li>
 +
                                <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Integrated_Practices">Integrated Practices</a></li>
 +
                                <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Engagement">Engagement</a></li>
 +
                            </ul>
 +
                        </li>
 +
                    </ul>
 +
                </li>
 +
                <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Modeling">MODELING</a></li>
 +
                <li class="dropdown">
 +
                    <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">TEAM<span class="caret"></span></a>
 +
                    <ul class="dropdown-menu">
 +
                        <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Team">Team</a></li>
 +
                        <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Attributions">Attributions</a></li>
 +
                        <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Collaborations">Collaborations</a></li>
 +
                    </ul>
 +
                </li>
 +
 +
                <li class="dropdown">
 +
                    <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">PARTS<span class="caret"></span></a>
 +
                    <ul class="dropdown-menu">
 +
                        <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Parts">Parts</a></li>
 +
                        <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Basic_Part">Basic Parts</a></li>
 +
                        <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Composite_Part">Composite Parts</a></li>
 +
                        <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Part_Collection">Part Collection</a></li>
 +
                    </ul>
 +
                </li>
 +
                <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Safety">SAFETY</a></li>
 +
                <li><a href="https://2016.igem.org/Team:SYSU-MEDICINE/Judging">JUDGING</a></li>
 +
            </ul>
 +
        </div><!-- /.navbar-collapse -->
 +
    </div><!-- /.container-fluid -->
 +
</nav>
 +
<!--content-->
 +
<div class="jumbotron">
 +
    <div class="my-content">
 +
        <h1 align="center">Proof of Concept</h1>
 +
    </div>
 +
</div>
 +
<div class="jumbotron" id="content">
 +
    <div class="mynav">
 +
 +
        <ol>
 +
            <li><a href="#Proof1">Expression</a>
 +
                <ol>
 +
                    <li><a href="#Proof1.1">Chemokine receptors</a></li>
 +
                    <li><a href="#Proof1.2">Marking proteins</a></li>
 +
                </ol>
 +
            </li>
 +
            <li><a href="#Proof2">Function</a>
 +
                <ol>
 +
                    <li><a href="#Proof2.1">Elevated homing ability</a></li>
 +
                    <li><a href="#Proof2.2">Locating</a></li>
 +
                </ol>
 +
            </li>
 +
            <li><a href="#Proof3">Identification</a>
 +
                <ol>
 +
                    <li><a href="#Proof3.1">Phenotypes of MSCs</a></li>
 +
                    <li><a href="#Proof3.2">Immunoregulatory function of MSCs</a></li>
 +
                </ol>
 +
            </li>
 +
        </ol>
 +
    </div>
 +
    <div class="my-content">
 +
        <p>
 +
            MSCalvary (our modified MSCs) is a set of MSCs engineered with specific chemokine receptors and marking proteins. This summer vacation, we constructed the following devices which were testified both in vivo and in vitro.<br/>
 +
 +
        </p>
 +
        <table>
 +
            <tr>
 +
                <td style="text-align: center">
 +
                    <img src="https://static.igem.org/mediawiki/2016/c/c6/T--SYSU-MEDICINE--project-3.1.1.png">
 +
                    <span class="note">
 +
                        Figure 3.1.1<br/>
 +
                        BBa_K1993009
 +
                    </span>
 +
                </td>
 +
                <td style="text-align: center">
 +
                    <img src="https://static.igem.org/mediawiki/2016/a/a0/T--SYSU-MEDICINE--project-3.1.2.png">
 +
                    <span class="note">
 +
                        Figure 3.1.2<br/>
 +
                        BBa_K1993005
 +
                    </span>
 +
                </td>
 +
            </tr>
 +
        </table>
 +
        <p><br/>With the purpose of increasing homing efficiency of MSCs and illustrating their distribution, we focused on three aspects of great importance for proof of our concept:<Br/>
 +
            - Whether our devices express as expected;<br/>
 +
            - Whether our parts properly exert their function;<br/>
 +
            - Whether MSCs are negatively influenced by our system.<br/>
 +
        </p>
 +
        <h2 id="Proof1">Expression</h2>
 +
        <p>
 +
            <b id="Proof1.1"><big>1 Chemokine receptors</big></b><br/>
 +
            To figure out whether our devices express properly, mRNA and protein levels of CXCR4 and CXCR5 of MSCs and our modified MSCs were semi-quantified and detected by qPCR and western blot, respectively. mRNA and protein levels of CXCR4 and CXCR5 all elevated in our modified MSCs.<br/>
 +
            <br/>
 +
 +
        </p>
 +
        <table>
 +
            <tr>
 +
                <td style="text-align: center; width: 300px">
 +
                    <img  src="https://static.igem.org/mediawiki/2016/0/0d/T--SYSU-MEDICINE--project-3.2.1.png">
 +
 +
                </td>
 +
                <td style="text-align: center; width: 300px">
 +
                    <img  src="https://static.igem.org/mediawiki/2016/2/2e/T--SYSU-MEDICINE--project-3.2.2.png">
 +
 +
                </td>
 +
                <td style="text-align: center; width: 300px">
 +
                    <img  src="https://static.igem.org/mediawiki/2016/f/fe/T--SYSU-MEDICINE--project-3.2.3.png">
 +
 +
                </td>
 +
            </tr>
 +
            <tr>
 +
                <td style="text-align: center;">
 +
                    <span class="note">
 +
                        Figure 3.2.1
 +
                    </span>
 +
                </td>
 +
                <td style="text-align: center;">
 +
                    <span  class="note">
 +
                        Figure 3.2.2
 +
                    </span>
 +
                </td>
 +
                <td  style="text-align: center;">
 +
                    <span class="note">
 +
                        Figure 3.2.3
 +
                    </span>
 +
                </td>
 +
            </tr>
 +
        </table>
 +
        <p>
 +
            <br/>
 +
            <b id="Proof1.2"><big>2 Marking proteins </big></b><br/>
 +
            - eGFP<Br/>
 +
            As for expression of eGFP, transfected 293T cells (Figure 3.2.4A: EF-1α-CXCR5-IRES-eGFP; Figure 3.2.4B: EF-1α-CXCR4-T2A-luciferase-IRES-eGFP) and MSCs (Figure 3.2.5A: EF-1α-CXCR5-IRES-eGFP; Figure 3.2.5B: EF-1α-CXCR4-T2A-luciferase-IRES-eGFP) were observed under fluorescent microscope. As a result, eGFP were expressed.<br/>
 +
            <br/>
 +
 +
        </p>
 +
        <table>
 +
            <tr>
 +
                <td style="text-align: center;width:430px">
 +
                    <img src="https://static.igem.org/mediawiki/2016/1/11/T--SYSU-MEDICINE--project-3.2.4.png">
 +
                    <span class="note">
 +
                        Figure 3.2.4
 +
                    </span>
 +
                </td>
 +
                <td style="text-align: center;width:430px">
 +
                    <img src="https://static.igem.org/mediawiki/2016/9/96/T--SYSU-MEDICINE--project-3.2.5.png">
 +
                    <span class="note">
 +
                        Figure 3.2.5
 +
                    </span>
 +
                </td>
 +
            </tr>
 +
        </table>
 +
        <p>
 +
            <br/>- Luciferase<br/>
 +
            Under IVIS Spectrum, MSCs with degraded luciferin could be clearly observed.<br/>
 +
            <Br/>
 +
            <img style="width: 300px" src="https://static.igem.org/mediawiki/2016/c/cb/T--SYSU-MEDICINE--project-3.2.6.png">
 +
            <span style="text-align: center;" class="note">
 +
                Figure 3.2.6<br/>
 +
            </span>
 +
            <br/>
 +
        </p>
 +
        <h2 id="Proof2">Function</h2>
 +
        <p>
 +
            <b id="Proof2.1"><big>1 Elevated homing ability</big></b><br/>
 +
            <br/>
 +
            In order to verify whether engineered MSCs successfully acquired elevated chemotaxis, in vivo and in vitro experiments were conducted.<br/>
 +
            <br/>
 +
            - In vitro verification<br/>
 +
            Chemotaxis of engineered MSCs were examined against CXCL12 and CXCL13 respectively. Results were reported as number of cells migrated. Chemotaxis capacity of our engineered MSCs all improved.<br/>
 +
            <br/>
 +
 +
        </p>
 +
        <table>
 +
            <tr>
 +
                <td style="text-align: center;width:450px">
 +
                    <img style="width:500px" src="https://static.igem.org/mediawiki/2016/3/32/T--SYSU-MEDICINE--project-3.3.1.png">
 +
                </td>
 +
                <td style="text-align: center;width:450px">
 +
                    <img style="width:500px" src="https://static.igem.org/mediawiki/2016/2/2e/T--SYSU-MEDICINE--project-3.3.2.png">
 +
                </td>
 +
            </tr>
 +
            <tr>
 +
                <td style="text-align: center;">
 +
                    <span class="note">
 +
                        Figure 3.3.1
 +
                    </span>
 +
                </td>
 +
                <td style="text-align: center;">
 +
                    <span  class="note">
 +
                        Figure 3.3.2
 +
                    </span>
 +
                </td>
 +
            </tr>
 +
            <tr ><span align="center">
 +
                <td align="center" style="text-align: center;width:450px">
 +
                    <img style="width:500px" src="">
 +
                </td></span>
 +
        </table>
 +
 +
        <img style="width:500px"src="https://static.igem.org/mediawiki/2016/8/84/T--SYSU-MEDICINE--project-3.3.3.png">
 +
        <span style="text-align: center;" class="note">
 +
                    Figure 3.3.3
 +
                </span>
 +
 +
        <p>
 +
            <br/>
 +
            - In vivo verification<br/>
 +
            <br/>
 +
            · Under IVIS Spectrum, MSCs<sup>CXCR4</sup> exhibited enhanced capacities for targeted migration to the bowels in IBD model.<br/>
 +
            <br/>
 +
            <img src="https://static.igem.org/mediawiki/2016/7/7c/T--SYSU-MEDICINE--project-3.3.4.png">
 +
            <span style="text-align: center;" class="note">
 +
                Figure 3.3.4
 +
            </span>
 +
            <br/>
 +
            · The inflamed ears were collected from each group and subjected to in situ immunofluorescence staining. Our results revealed that MSCs<sup>CXCR5</sup> exhibited enhanced capacities for targeted migration to the ears in DTH model.<br/>
 +
            <Br/>
 +
            <img src="https://static.igem.org/mediawiki/2016/c/c5/T--SYSU-MEDICINE--project-3.3.5.png">
 +
            <span style="text-align: center;" class="note">
 +
                Figure 3.3.5
 +
            </span>
 +
            <br/>
 +
            <b id="Proof2.2"><big>2 Locating</big></b><br/>
 +
            · Under IVIS Spectrum, MSCs<sup>CXCR4</sup> could be detected and located in IBD mice.<br/>
 +
            <Br/>
 +
            <img style="width: 300px" src="https://static.igem.org/mediawiki/2016/1/19/T--SYSU-MEDICINE--project-3.3.6.png">
 +
            <span style="text-align: center;" class="note">
 +
                Figure 3.3.6<br/>
 +
            </span>
 +
            <br/>
 +
            · The inflamed ears were collected from each group, subjected to in situ immunofluorescence staining and observed under fluorescence microscope. Our results revealed MSCs<sup>CXCR5</sup> could be located in the inflamed ears of DTH mice.<br/>
 +
            <br/>
 +
            <img style="width: 300px" src="https://static.igem.org/mediawiki/2016/e/e7/T--SYSU-MEDICINE--project-3.3.7.png">
 +
            <span style="text-align: center;" class="note">
 +
                Figure 3.3.7<br/>
 +
            </span>
 +
            <br/>
 +
 +
        </p>
 +
        <h2 id="Proof3">Identification</h2>
 +
        <p>Our modified MSCs still remained their own characteristics, including phenotypes and Immunoregulatory function.<br/>
 +
 +
            <b id="Proof3.1"><big>1 Phenotypes of MSCs</big></b><br/>
 +
            Our modified MSCs were still positive for CD105, CD90, CD29 and CD73 and negative for CD34 (Figure 3.4.1 A-E), and were able to differentiate to osteoblasts, adipocytes, and chondroblasts under standard in vitro differentiating conditions (Figure 3.4.2 F-K). (Meet the standard of International Society for Cellular Therapy (ISCT))<br/>
 +
            <br/>
 +
 +
        </p>
 +
        <table>
 +
            <tr>
 +
                <td style="text-align: center;width:450px">
 +
                    <img src="https://static.igem.org/mediawiki/2016/b/b0/T--SYSU-MEDICINE--project-3.4.1.png">
 +
                </td>
 +
                <td style="text-align: center;width:450px">
 +
                    <img src="https://static.igem.org/mediawiki/2016/6/6d/T--SYSU-MEDICINE--project-3.4.2.png">
 +
                </td>
 +
            </tr>
 +
            <tr>
 +
                <td style="text-align: center;">
 +
                    <span class="note">
 +
                        Figure 3.4.1
 +
                    </span>
 +
                </td>
 +
                <td style="text-align: center;">
 +
                    <span  class="note">
 +
                        Figure 3.4.2
 +
                    </span>
 +
                </td>
 +
            </tr>
 +
        </table>
 +
 +
        <p>
 +
            <br/>
 +
            <b id="Proof3.2"><big>2 Immunoregulatory function of MSCs</big></b><br/>
 +
            For MSCs<sup>CXCR4</sup><br/>
 +
            · Colon sampling for quantitative PCR analysis. Comparing with TNBS+MSC group, levels of the anti-inflammatory cytokine (IL-10) elevated in TNBS+MSCs<sup>CXCR4</sup> group while pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) levels decreased in TNBS+ MSCs<sup>CXCR4</sup> group. In a word, MSCs<sup>CXCR4</sup> have greater immunoregulatory function.<br/>
 +
            <br/>
 +
 +
        </p>
 +
 +
        <p align="center">
 +
        <table>
 +
            <tr>
 +
                <td style="text-align: center;width:225px">
 +
                    <img style="width:500px" src="https://static.igem.org/mediawiki/2016/f/f3/T--SYSU-MEDICINE--project-3.4.3.png">
 +
                </td>
 +
 +
                <td style="text-align: center;width:225px">
 +
                    <img style="width:500px" src="https://static.igem.org/mediawiki/2016/d/d5/T--SYSU-MEDICINE--project-3.4.4.png">
 +
                </td>
 +
            </tr>
 +
            <tr>
 +
                <td style="text-align: center;">
 +
                    <span class="note">
 +
                    Figure 3.4.3
 +
                    </span>
 +
                </td>
 +
                <td style="text-align: center;">
 +
                <span  class="note">
 +
                Figure 3.4.4
 +
                </span>
 +
                </td>
 +
 +
            </tr>
 +
            <tr>
 +
                <td style="text-align: center;width:225px">
 +
                    <img style="width:500px" src="https://static.igem.org/mediawiki/2016/d/d0/T--SYSU-MEDICINE--project-3.4.5.png">
 +
                </td>
 +
                <td style="text-align: center;width:225px">
 +
                    <img style="width:500px" src="https://static.igem.org/mediawiki/2016/2/27/T--SYSU-MEDICINE--project-3.4.6.png">
 +
                </td>
 +
            </tr>
 +
            <tr>
 +
                <td style="text-align: center;">
 +
                    <span class="note">
 +
                        Figure 3.4.5
 +
                    </span>
 +
                </td>
 +
                <td style="text-align: center;">
 +
                    <span  class="note">
 +
                        Figure 3.4.6
 +
                    </span>
 +
                </td>
 +
            </tr>
 +
        </table></p>
 +
 +
        <p>
 +
            <br/>
 +
            · After injecting with MSCs<sup>CXCR4</sup>, survival rate, body weight, length of colon and DAI score of IBD mice were improved significantly comparing to TNBS+MSC group and TNBS+saline group. In a word, MSCs<sup>CXCR4</sup> have greater immunoregulatory function.<br/>
 +
            <br/>
 +
 +
        </p>
 +
        <p align="center">
 +
        <table>
 +
            <tr>
 +
                <td style="text-align: center;width:225px">
 +
                    <img style="width:500px" src="https://static.igem.org/mediawiki/2016/6/62/T--SYSU-MEDICINE--project-3.4.7.png">
 +
                </td>
 +
                <td style="text-align: center;width:225px">
 +
                    <img style="width:500px" src="https://static.igem.org/mediawiki/2016/8/8f/T--SYSU-MEDICINE--project-3.4.8.png">
 +
                </td>
 +
            </tr>
 +
            <tr>
 +
                <td style="text-align: center;">
 +
      <span class="note">
 +
          Figure 3.4.7
 +
      </span>
 +
                </td>
 +
                <td style="text-align: center;">
 +
      <span  class="note">
 +
          Figure 3.4.8
 +
      </span>
 +
                </td>
 +
 +
            </tr>
 +
 +
            <tr>
 +
 +
                <td style="text-align: center;width:225px">
 +
                    <img style="width:500px" src="https://static.igem.org/mediawiki/2016/4/4f/T--SYSU-MEDICINE--project-3.4.9.png">
 +
                </td>
 +
                <td style="text-align: center;width:225px">
 +
                    <img style="width:500px" src="https://static.igem.org/mediawiki/2016/6/60/T--SYSU-MEDICINE--project-3.4.10.png">
 +
                </td>
 +
            </tr>
 +
 +
 +
            <tr>
 +
 +
                <td style="text-align: center;">
 +
                    <span class="note">
 +
                        Figure 3.4.9
 +
                    </span>
 +
                </td>
 +
                <td style="text-align: center;">
 +
                    <span  class="note">
 +
                        Figure 3.4.10
 +
                    </span>
 +
                </td>
 +
            </tr>
 +
        </table></p>
 +
        <p>
 +
            <br/>
 +
            · Photographs of hematoxylin/eosin-stained colon cross-sections 2 days after injecting MSCs. MSCs<sup>CXCR4</sup> displayed better treatment efficacy than TNBS+MSC group and TNBS+saline group, characterized by their abilities to decrease leukocyte infiltration. In a word, MSCs<sup>CXCR4</sup> have greater immunoregulatory function.<br/>
 +
            <br/>
 +
            <img src="https://static.igem.org/mediawiki/2016/e/e0/T--SYSU-MEDICINE--project-3.4.11.png">
 +
            <span style="text-align: center;" class="note">
 +
                Figure 3.4.11<br/>
 +
            </span>
 +
            <br/>
 +
            For MSCs<sup>CXCR5</sup><br/>
 +
            · Ear sampling for quantitative PCR analysis. Comparing with DTH+MSCs group, levels of the anti-inflammatory cytokines (IL-10), elevated in DTH+MSCs<sup>CXCR5</sup> group, while levels of pro-inflammatory cytokines (IL-4, TNF-α, IFN-γ, IL-6 and IL-17) decreased in DTH+MSCs<sup>CXCR5</sup> group. In a word, MSCs<sup>CXCR5</sup> have greater immunoregulatory function.<br/>
 +
            <br/>
 +
            <img src="https://static.igem.org/mediawiki/2016/3/3e/T--SYSU-MEDICINE--project-3.4.12.png">
 +
            <span style="text-align: center;" class="note">
 +
                Figure 3.4.12<br/>
 +
            </span>
 +
            <br/>
 +
            · After injection, MSCs<sup>CXCR5</sup> displayed better treatment efficacy than DTH+MSCs<sup>eGFP</sup> group, characterized by their abilities to decrease ear thickness and leukocyte infiltration. MSCs<sup>CXCR5</sup> significantly attenuated DTH as early as 24 hours post-injection, and had even greater effects at 48 hours post-injection. In a word, MSCs<sup>CXCR5</sup> have greater immunoregulatory function.<br/>
 +
            <br/>
 +
            <img src="https://static.igem.org/mediawiki/2016/e/e4/T--SYSU-MEDICINE--project-3.4.13.png">
 +
            <span style="text-align: center;" class="note">
 +
                Figure 3.4.13<br/>
 +
            </span>
 +
            <br/>
 +
            <img style="width: 500px" src="https://static.igem.org/mediawiki/2016/9/93/T--SYSU-MEDICINE--project-3.4.14.png">
 +
            <span style="text-align: center;" class="note">
 +
                Figure 3.4.14<br/>
 +
            </span>
 +
            <br/>
 +
        </p>
 +
    </div>
 +
</div>
 +
 +
<!--footer-->
 +
<div class="jumbotron" id="jumbo-footer">
 +
    <div class="footer-container">
 +
        <div class="title">
 +
            Contact us
 +
        </div>
 +
        <div class="line"></div>
 +
        <div class="contact">
 +
            <ul class="float-contact">
 +
                <li>
 +
                    <a href="http://weibo.com/u/5999650333">
 +
                        <img style="height: 32px; width: 32px" src="https://static.igem.org/mediawiki/2016/0/06/T--SYSU-MEDICINE--weibo.png">
 +
                        iGEMxSYSU-MEDICINE
 +
                    </a>
 +
                </li>
 +
                <li>
 +
                    <a href="https://www.facebook.com/IGEM-SYSU-Medicine">
 +
                        <img style="height: 27px; width: 27px; margin-left: 2px;margin-right:2px;" src="https://static.igem.org/mediawiki/2016/a/a1/T--SYSU-MEDICINE--facebook.png">
 +
                        IGEM SYSU-Medicine
 +
                    </a>
 +
                </li>
 +
                <li>
 +
                    <a href="#">
 +
                        <img src="https://static.igem.org/mediawiki/2016/4/43/T--SYSU-MEDICINE--email.png">
 +
                        SYSU_MEDICINE@163.com
 +
                    </a>
 +
                </li>
 +
            </ul>
 +
            <ul class="float-contact">
 +
                <li>
 +
                    <a href="#" data-toggle="modal" data-target="#wechatModal">
 +
                        <img src="https://static.igem.org/mediawiki/2016/6/6e/T--SYSU-MEDICINE--wechat.png">
 +
                        SYSU-MEDICINE
 +
                    </a>
 +
                </li>
 +
                <li>
 +
                    <a href="https://twitter.com/IgemSysu">
 +
                        <img src="https://static.igem.org/mediawiki/2016/1/1c/T--SYSU-MEDICINE--twitter.png">
 +
                        iGEM SYSU-MEDICINE
 +
                    </a>
 +
                </li>
 +
 +
            </ul>
 +
            <div class="float-contact-right">
 +
                <img style="width: 140px" src="https://static.igem.org/mediawiki/2016/5/5e/T--SYSU-MEDICINE--Igemlogo_banner.png">
 +
                <img style="height: 100px" src="https://static.igem.org/mediawiki/2016/d/df/T--SYSU-MEDICINE--SYSU-MEDICINE.png">
 +
            </div>
 +
        </div>
 +
        <div class="line"></div>
 +
        <div class="copyright">
 +
            <div class="text">
 +
                &copy; 2016 SYSU-MEDICINE. All Rights Reserved.
 +
            </div>
 +
            <div class="icon" >
 +
                <img src="https://static.igem.org/mediawiki/2016/f/f5/T--SYSU-MEDICINE--china_2x.png">
 +
                <img src="https://static.igem.org/mediawiki/2016/a/a9/T--SYSU-MEDICINE--SYSU.png">
 +
            </div>
 +
        </div>
 +
    </div>
 +
 +
</div>
 +
 +
<!-- Wechat QRCode Modal -->
 +
<div class="modal fade" id="wechatModal" tabindex="-1" role="dialog" aria-labelledby="myModalLabel" data-backdrop="false">
 +
    <div class="modal-dialog" role="document">
 +
        <div class="modal-content">
 +
 +
            <div class="modal-body">
 +
                <img style="height: 300px;width: 300px;" src="https://static.igem.org/mediawiki/2016/0/07/T--SYSU-MEDICINE--wechat-qrcode.png">
 +
            </div>
 +
 +
        </div>
 +
    </div>
 +
</div>
 +
</body>
 
</html>
 
</html>

Latest revision as of 00:04, 20 October 2016

Proof of Concept

MSCalvary (our modified MSCs) is a set of MSCs engineered with specific chemokine receptors and marking proteins. This summer vacation, we constructed the following devices which were testified both in vivo and in vitro.

Figure 3.1.1
BBa_K1993009
Figure 3.1.2
BBa_K1993005


With the purpose of increasing homing efficiency of MSCs and illustrating their distribution, we focused on three aspects of great importance for proof of our concept:
- Whether our devices express as expected;
- Whether our parts properly exert their function;
- Whether MSCs are negatively influenced by our system.

Expression

1 Chemokine receptors
To figure out whether our devices express properly, mRNA and protein levels of CXCR4 and CXCR5 of MSCs and our modified MSCs were semi-quantified and detected by qPCR and western blot, respectively. mRNA and protein levels of CXCR4 and CXCR5 all elevated in our modified MSCs.

Figure 3.2.1 Figure 3.2.2 Figure 3.2.3


2 Marking proteins
- eGFP
As for expression of eGFP, transfected 293T cells (Figure 3.2.4A: EF-1α-CXCR5-IRES-eGFP; Figure 3.2.4B: EF-1α-CXCR4-T2A-luciferase-IRES-eGFP) and MSCs (Figure 3.2.5A: EF-1α-CXCR5-IRES-eGFP; Figure 3.2.5B: EF-1α-CXCR4-T2A-luciferase-IRES-eGFP) were observed under fluorescent microscope. As a result, eGFP were expressed.

Figure 3.2.4 Figure 3.2.5


- Luciferase
Under IVIS Spectrum, MSCs with degraded luciferin could be clearly observed.

Figure 3.2.6

Function

1 Elevated homing ability

In order to verify whether engineered MSCs successfully acquired elevated chemotaxis, in vivo and in vitro experiments were conducted.

- In vitro verification
Chemotaxis of engineered MSCs were examined against CXCL12 and CXCL13 respectively. Results were reported as number of cells migrated. Chemotaxis capacity of our engineered MSCs all improved.

Figure 3.3.1 Figure 3.3.2
Figure 3.3.3


- In vivo verification

· Under IVIS Spectrum, MSCsCXCR4 exhibited enhanced capacities for targeted migration to the bowels in IBD model.

Figure 3.3.4
· The inflamed ears were collected from each group and subjected to in situ immunofluorescence staining. Our results revealed that MSCsCXCR5 exhibited enhanced capacities for targeted migration to the ears in DTH model.

Figure 3.3.5
2 Locating
· Under IVIS Spectrum, MSCsCXCR4 could be detected and located in IBD mice.

Figure 3.3.6

· The inflamed ears were collected from each group, subjected to in situ immunofluorescence staining and observed under fluorescence microscope. Our results revealed MSCsCXCR5 could be located in the inflamed ears of DTH mice.

Figure 3.3.7

Identification

Our modified MSCs still remained their own characteristics, including phenotypes and Immunoregulatory function.
1 Phenotypes of MSCs
Our modified MSCs were still positive for CD105, CD90, CD29 and CD73 and negative for CD34 (Figure 3.4.1 A-E), and were able to differentiate to osteoblasts, adipocytes, and chondroblasts under standard in vitro differentiating conditions (Figure 3.4.2 F-K). (Meet the standard of International Society for Cellular Therapy (ISCT))

Figure 3.4.1 Figure 3.4.2


2 Immunoregulatory function of MSCs
For MSCsCXCR4
· Colon sampling for quantitative PCR analysis. Comparing with TNBS+MSC group, levels of the anti-inflammatory cytokine (IL-10) elevated in TNBS+MSCsCXCR4 group while pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) levels decreased in TNBS+ MSCsCXCR4 group. In a word, MSCsCXCR4 have greater immunoregulatory function.

Figure 3.4.3 Figure 3.4.4
Figure 3.4.5 Figure 3.4.6


· After injecting with MSCsCXCR4, survival rate, body weight, length of colon and DAI score of IBD mice were improved significantly comparing to TNBS+MSC group and TNBS+saline group. In a word, MSCsCXCR4 have greater immunoregulatory function.

Figure 3.4.7 Figure 3.4.8
Figure 3.4.9 Figure 3.4.10


· Photographs of hematoxylin/eosin-stained colon cross-sections 2 days after injecting MSCs. MSCsCXCR4 displayed better treatment efficacy than TNBS+MSC group and TNBS+saline group, characterized by their abilities to decrease leukocyte infiltration. In a word, MSCsCXCR4 have greater immunoregulatory function.

Figure 3.4.11

For MSCsCXCR5
· Ear sampling for quantitative PCR analysis. Comparing with DTH+MSCs group, levels of the anti-inflammatory cytokines (IL-10), elevated in DTH+MSCsCXCR5 group, while levels of pro-inflammatory cytokines (IL-4, TNF-α, IFN-γ, IL-6 and IL-17) decreased in DTH+MSCsCXCR5 group. In a word, MSCsCXCR5 have greater immunoregulatory function.

Figure 3.4.12

· After injection, MSCsCXCR5 displayed better treatment efficacy than DTH+MSCseGFP group, characterized by their abilities to decrease ear thickness and leukocyte infiltration. MSCsCXCR5 significantly attenuated DTH as early as 24 hours post-injection, and had even greater effects at 48 hours post-injection. In a word, MSCsCXCR5 have greater immunoregulatory function.

Figure 3.4.13

Figure 3.4.14